Cannabis in the News

Former FDA Commissioner Publishes Op-Ed Opinion on Federal Law Compromise

By October 12, 2019 No Comments

Gottlieb, former FDA Commissioner, published an op-ed yesterday in The Wall Street Journal on federal cannabis regulations and state cannabis regulations. In the op-ed, the former FDA Commissioner called for the federal government to compromise on the federal law with tetrahydrocannabinol (THC). The current stance of federal law is separated by a stark contrast with state laws that have legalized medical or recreational cannabis. There are currently 11 recreational states and 33 medical cannabis states that conflict with the Schedule 1 status of cannabis in the federal government. Former FDA Commissioner Scott Gottlieb wants the federal government to be able to step in and do what it is good at, regulation held at federal standards.

“…Regulation of the potency of THC compounds, the forms they take, how they’re manufactured, and who can make purchases ought to be possible,” said Gottlieb.

Gottlieb’s proposed regulation by the federal government on products, such as THC vape pens, would close the gap between state and federal agencies. He has come out in the past to point out the lack of regulations between the two entities that caused vape pens to be regulated at “an impasse”.

“THC is currently illegal under federal law,” he said. “Right now there’s no middle ground allowing federal agencies to scrutinize these compounds for their manufacturing, marketing and safety,” he said.

The overall goal of former FDA Commissioner Gottlieb’s op-end piece, in the end, isn’t clear exactly what he’s asking Congress and the federal government to do. He stopped short of full federal government de-scheduling, but a relationship between federal and state governments is definitely wanted.

Curious about how you can make money investing in cannabis? Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll keep you informed on all things cannabis and even help you determine which cannabis companies have the highest growth potential.